Tags

Type your tag names separated by a space and hit enter

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Pathol Oncol Res 2008; 14(4):411-21PO

Abstract

Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL). Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity. We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004. Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients. Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease. None of the patients showed extranodal or splenic involvement or bulky disease. One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment. We applied watch and wait strategy in three cases. Overall response rate was 100% (93.75% complete). Two NLPHL cases transformed to non-Hodgkin's lymphoma. In contrast to the classical HL, the 10-year prognosticated overall survival rate was 100 vs. 82%, the event free survival was: 75% vs. 70%. In NLPHL group there were no late or multiple relapses and none of them died.

CONCLUSIONS

NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment. Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.

Authors+Show Affiliations

3rd Department of Institute for Internal Medicine, Medical and Health Science Centre, University of Debrecen, 4032, Debrecen, Hungary.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

18431694

Citation

Illés, A, et al. "Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)-clinicopathological Features Based On the Data of Two Hungarian Lymphoma Centres." Pathology Oncology Research : POR, vol. 14, no. 4, 2008, pp. 411-21.
Illés A, Simon Z, Tóth E, et al. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res. 2008;14(4):411-21.
Illés, A., Simon, Z., Tóth, E., Rosta, A., Miltényi, Z., & Molnár, Z. (2008). Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathology Oncology Research : POR, 14(4), pp. 411-21. doi:10.1007/s12253-008-9043-y.
Illés A, et al. Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)-clinicopathological Features Based On the Data of Two Hungarian Lymphoma Centres. Pathol Oncol Res. 2008;14(4):411-21. PubMed PMID: 18431694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. AU - Illés,A, AU - Simon,Zs, AU - Tóth,E, AU - Rosta,A, AU - Miltényi,Zs, AU - Molnár,Zs, Y1 - 2008/04/23/ PY - 2008/03/12/received PY - 2008/03/31/accepted PY - 2008/4/24/pubmed PY - 2009/5/1/medline PY - 2008/4/24/entrez SP - 411 EP - 21 JF - Pathology oncology research : POR JO - Pathol. Oncol. Res. VL - 14 IS - 4 N2 - UNLABELLED: Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL). Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity. We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004. Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients. Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease. None of the patients showed extranodal or splenic involvement or bulky disease. One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment. We applied watch and wait strategy in three cases. Overall response rate was 100% (93.75% complete). Two NLPHL cases transformed to non-Hodgkin's lymphoma. In contrast to the classical HL, the 10-year prognosticated overall survival rate was 100 vs. 82%, the event free survival was: 75% vs. 70%. In NLPHL group there were no late or multiple relapses and none of them died. CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment. Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population. SN - 1219-4956 UR - https://www.unboundmedicine.com/medline/citation/18431694/Nodular_lymphocyte_predominant_Hodgkin_lymphoma__NLPHL__clinicopathological_features_based_on_the_data_of_two_Hungarian_lymphoma_centres_ L2 - https://doi.org/10.1007/s12253-008-9043-y DB - PRIME DP - Unbound Medicine ER -